Literature DB >> 15602687

Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats.

Paul J Kenny1, Benjamin Boutrel, Fabrizio Gasparini, George F Koob, Athina Markou.   

Abstract

RATIONALE: Evidence is accumulating that metabotropic glutamate 5 (mGlu5) receptors play an important role in regulating the reinforcing actions of drugs of abuse.
OBJECTIVES: We examined the effects of the mGlu5 receptor antagonist MPEP on cocaine consumption and cocaine-enhanced brain reward function in rats.
METHODS: Cocaine consumption was measured in rats with 1 h (short-access; ShA) or 6 h (long-access; LgA) daily access to intravenous cocaine (0.25 mg/infusion) self-administration. Cocaine-enhanced brain reward function was measured by cocaine-induced lowering of intracranial self-stimulation (ICSS) thresholds.
RESULTS: Cocaine consumption remained stable and unaltered over successive self-administration sessions in ShA rats. In contrast, cocaine consumption progressively "escalated" in LgA rats. MPEP (1--9 mg/kg) dose-dependently decreased responding similarly in ShA and LgA rats. These data suggest that mGlu5 receptors regulate the reinforcing properties of cocaine, and that this action of mGlu5 receptors is independent of the escalation in consumption associated with extended access to cocaine self-administration. MPEP doses (1--9 mg/kg) that decreased cocaine self-administration elevated brain reward thresholds to a similar degree in cocaine- and vehicle-treated rats, indicating that MPEP induced a negative affective state. The additive effects of MPEP and cocaine on thresholds resulted in attenuation of the magnitude of cocaine-induced (10 mg/kg) lowering of ICSS thresholds.
CONCLUSIONS: Overall, mGlu5 receptors appear to play an important role in regulating cocaine consumption, and also in regulating brain reward function. Further, it is likely that blockade of mGlu5 receptors may attenuate cocaine consumption, at least in part, by decreasing the baseline activity of brain reward circuitries.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15602687     DOI: 10.1007/s00213-004-2069-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  38 in total

1.  Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice.

Authors:  C Chiamulera; M P Epping-Jordan; A Zocchi; C Marcon; C Cottiny; S Tacconi; M Corsi; F Orzi; F Conquet
Journal:  Nat Neurosci       Date:  2001-09       Impact factor: 24.884

2.  Low dose cocaine self-administration transiently increases but high dose cocaine persistently decreases brain reward function in rats.

Authors:  Paul J Kenny; Ilham Polis; George F Koob; Athina Markou
Journal:  Eur J Neurosci       Date:  2003-01       Impact factor: 3.386

3.  Role of unconditioned and conditioned drug effects in the self-administration of opiates and stimulants.

Authors:  J Stewart; H de Wit; R Eikelboom
Journal:  Psychol Rev       Date:  1984-04       Impact factor: 8.934

4.  Long-term potentiation of excitatory inputs to brain reward areas by nicotine.

Authors:  H D Mansvelder; D S McGehee
Journal:  Neuron       Date:  2000-08       Impact factor: 17.173

5.  Brain neurotransmitter turnover rates during rat intravenous cocaine self-administration.

Authors:  J E Smith; T R Koves; C Co
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

6.  Critical role for ventral tegmental glutamate in preference for a cocaine-conditioned environment.

Authors:  Glenda C Harris; Gary Aston-Jones
Journal:  Neuropsychopharmacology       Date:  2003-01       Impact factor: 7.853

7.  The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse.

Authors:  Andrew J McGeehan; M Foster Olive
Journal:  Synapse       Date:  2003-03       Impact factor: 2.562

8.  The motivational valence of nicotine in the rat ventral tegmental area is switched from rewarding to aversive following blockade of the alpha7-subunit-containing nicotinic acetylcholine receptor.

Authors:  Steven R Laviolette; Derek van der Kooy
Journal:  Psychopharmacology (Berl)       Date:  2003-02-05       Impact factor: 4.530

9.  Desmethylimipramine attenuates cocaine withdrawal in rats.

Authors:  A Markou; R L Hauger; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats.

Authors:  Paul J Kenny; Fabrizio Gasparini; Athina Markou
Journal:  J Pharmacol Exp Ther       Date:  2003-06-12       Impact factor: 4.030

View more
  73 in total

1.  mGlu receptors and drug addiction.

Authors:  Richard M Cleva; M Foster Olive
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2012-01-20

2.  Involvement of metabotropic glutamate receptor 5 in brain reward deficits associated with cocaine and nicotine withdrawal and somatic signs of nicotine withdrawal.

Authors:  Astrid K Stoker; Berend Olivier; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2011-12-03       Impact factor: 4.530

3.  Activation of mGluR7s inhibits cocaine-induced reinstatement of drug-seeking behavior by a nucleus accumbens glutamate-mGluR2/3 mechanism in rats.

Authors:  Xia Li; Jie Li; Eliot L Gardner; Zheng-Xiong Xi
Journal:  J Neurochem       Date:  2010-06-08       Impact factor: 5.372

Review 4.  Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction.

Authors:  M Foster Olive
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

5.  Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects.

Authors:  Robert W Gould; Russell J Amato; Michael Bubser; Max E Joffe; Michael T Nedelcovych; Analisa D Thompson; Hilary H Nickols; Johannes P Yuh; Xiaoyan Zhan; Andrew S Felts; Alice L Rodriguez; Ryan D Morrison; Frank W Byers; Jerri M Rook; John S Daniels; Colleen M Niswender; P Jeffrey Conn; Kyle A Emmitte; Craig W Lindsley; Carrie K Jones
Journal:  Neuropsychopharmacology       Date:  2015-08-28       Impact factor: 7.853

6.  Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats.

Authors:  Matthias E Liechti; Athina Markou
Journal:  Eur J Pharmacol       Date:  2006-10-17       Impact factor: 4.432

7.  Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists.

Authors:  Santosh S Kulkarni; Mu-Fa Zou; Jianjing Cao; Jeffrey R Deschamps; Alice L Rodriguez; P Jeffrey Conn; Amy Hauck Newman
Journal:  J Med Chem       Date:  2009-06-11       Impact factor: 7.446

8.  Acamprosate attenuates cocaine- and cue-induced reinstatement of cocaine-seeking behavior in rats.

Authors:  M Scott Bowers; Billy T Chen; Jonathan K Chou; Megan P H Osborne; Justin T Gass; Ronald E See; Antonello Bonci; Patricia H Janak; M Foster Olive
Journal:  Psychopharmacology (Berl)       Date:  2007-09-02       Impact factor: 4.530

9.  Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography.

Authors:  Funda Akkus; Simon M Ametamey; Valerie Treyer; Cyrill Burger; Anass Johayem; Daniel Umbricht; Baltazar Gomez Mancilla; Judit Sovago; Alfred Buck; Gregor Hasler
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

10.  Differential effects of MPEP and diazepam in tests of conditioned emotional response and Pavlovian-to-instrumental transfer suggests 'anxiolytic' effects are mediated by different mechanisms.

Authors:  S A George; P H Hutson; D N Stephens
Journal:  Psychopharmacology (Berl)       Date:  2009-02-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.